# Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

> **NCT00116649** · PHASE4 · COMPLETED · sponsor: **Graceway Pharmaceuticals, LLC** · enrollment: 551 (actual)

## Conditions studied

- Keratosis

## Interventions

- **DRUG:** imiquimod cream

## Key facts

- **NCT ID:** NCT00116649
- **Lead sponsor:** Graceway Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 551 (ACTUAL)
- **Last updated:** 2010-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116649, "Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00116649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*